Enliven Therapeutics (ELVN) CEO Amends Form 4 to Report 1,517-Share Sale

Rhea-AI Filing Summary

Samuel Kintz, President & CEO and Director of Enliven Therapeutics, Inc. (ELVN), reported an amended Form 4 showing a small open-market sale. The amendment corrects the original filing to reflect the disposition of 1,517 shares sold on 08/20/2025 under a Rule 10b5-1 trading plan adopted 11/15/2024 at a weighted average price of $20.0023 per share. After the sale, the reporting person beneficially owns 927,892 shares indirectly through The Kintz & Egan Trust dated March 30, 2019, for which he serves as trustee.

The amended filing was signed by power of attorney on 08/21/2025. The filer notes the sale was effected in multiple trades and offers to provide detailed execution prices on request.

Positive

• Sale executed under a Rule 10b5-1 plan, indicating pre-planned and compliant insider trading
• Amendment corrects prior omission, improving transparency and regulatory disclosure
• Disclosed indirect ownership via trust, clarifying beneficial ownership structure

Negative

• Insider sale of 1,517 shares reduces insider holdings, although modest in size

Insights

Securities Analyst

TL;DR: A routine, small insider sale under a pre-established 10b5-1 plan; amendment improves disclosure but is not materially market-moving.

The sale of 1,517 shares represents roughly 0.16% of the 927,892 shares reported beneficially owned, indicating a de minimis reduction in economic exposure. Execution under a Rule 10b5-1 plan and the filing amendment both support compliance and transparency. Investors should note the weighted average sale price of $20.0023, but there is no indication of change to insider ownership strategy beyond the planned sale mechanism.

Corporate Governance Expert

TL;DR: Amendment and 10b5-1 use signal procedural compliance and predictable selling, limiting governance concerns.

Filing an amendment to disclose the omitted sale and confirming the trade was executed pursuant to a November 15, 2024 10b5-1 plan demonstrates adherence to insider-trading controls and disclosure obligations. The indirect ownership via a trust where the reporting person is trustee is disclosed, clarifying beneficial ownership structure. The modest sale size reduces the likelihood of governance implications tied to management confidence or liquidity needs.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kintz Samuel

(Last) (First) (Middle)

C/O ENLIVEN THERAPEUTICS, INC.

6200 LOOKOUT ROAD

(Street)

BOULDER CO 80301

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Enliven Therapeutics, Inc. [ ELVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	PRESIDENT AND CEO

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)
08/20/2025

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	08/20/2025		S(2)		1,517	D	$20.0023(3)	927,892	I	See footnote(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The original Form 4, filed August 20, 2025, did not reflect the stock sale on August 20, 2025.

2. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 15, 2024.

3. This transaction was executed in multiple trades at prices ranging from $20.00 to $20.03. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

4. The shares are held of record by The Kintz & Egan Trust Dated March 30, 2019 for which the reporting person serves as trustee.

	/s/ Ben Hohl, by power of attorney	08/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Samuel Kintz report on the amended Form 4 for ELVN?

The amended Form 4 reports a sale of 1,517 shares on 08/20/2025 executed under a Rule 10b5-1 plan with a weighted average price of $20.0023.

How many ELVN shares does the reporting person beneficially own after the sale?

The filing reports 927,892 shares beneficially owned following the reported transaction, held indirectly through The Kintz & Egan Trust dated March 30, 2019.

Was the sale part of a pre-established trading plan?

Yes. The sales were effected pursuant to a Rule 10b5-1 trading plan adopted on November 15, 2024.

Why was this Form 4 amended?

The filer states the original Form 4 filed August 20, 2025 did not reflect the stock sale on that date, so this amendment adds the omitted sale.

Who signed the amended Form 4?

The form was signed by Ben Hohl by power of attorney on 08/21/2025.